NICE Raised to Outperform From Perform by Oppenheimer
Ratings actions from Benzinga: GMT) NICE Price Target Announced at $150.00/Share by OppenheimerRatings actions from Benzinga
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
6 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Full Transcript: Rockwell Automation Q3 2026 Earnings Call
Rockwell Automation (NYSE: ROK ) reported third-quarter financial results on Tuesday. The transcript from the company's third-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. Access the full call at Summary Rockwell Automa
VEON Q2 2026 Earnings Call: Complete Transcript
On Friday, VEON (NASDAQ: VEON ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. View the webcast at Summary VEON reported strong financial results for the secon
Forgent Power Solutions Q4 2026 Earnings Call Transcript
Forgent Power Solutions (NYSE: FPS ) reported fourth-quarter financial results on Tuesday. The transcript from the company's fourth-quarter earnings call has been provided below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. View the webcast at Summ
Transcript: Kestra Medical Techs Q1 2027 Earnings Conference Call
Kestra Medical Techs (NASDAQ: KMTS ) released first-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. The full earnings call is available at Summary Kestra Medical Techs
DocuSign raises fiscal 2027 ARR guidance after Q2 results
DocuSign reported Q2 revenue of $876 million, up 9% year over year, with a 32% operating margin and about $300 million in free cash flow. It also raised fiscal 2027 ARR guidance and said IAM now accounts for 15.1% of total ARR.